Opinion - Brace yourself: Trump's trade war is about to make Americans poorer
Move over, Smoot and Hawley. President Trump has anointed himself America's greatest protectionist, and he's launching a global trade war to prove it.
On Wednesday, Trump slapped a minimum 10 percent tariff on all imports, plus additional 'reciprocal' tariffs on 60 other countries that have the temerity to sell us things we want to buy. He dubbed it 'Liberation Day' to mark the freeing of Americans from the supposedly oppressive burden of trading with others.
Steeped in nostalgia for America's industrial heyday, Trump imagines he can unilaterally restructure the world's economy. The president can sign all the executive orders he pleases, but he can't throw history into reverse or repeal basic economics.
His universal tariffs constitute a massive tax hike on U.S. consumers, hitting everything from European medicines and Mexican fruits and vegetables to Vietnamese shoes and German cars. Likewise for Japanese or Korean steel and Canadian aluminum and electricity.
Meanwhile, our $3 trillion export sector — satellites and medical devices, soybeans and wine, movies and telemedicine — will shrink as other countries inevitably retaliate by hiking their tariffs.
Unless Trump relents, choking off trade with high tariffs will send prices soaring again, slow down economic growth, make Americans poorer and embroil us in mutually ruinous global trade wars with friends and allies.
The last time that happened, a wave of protectionism across the United States and Europe intensified and prolonged the economic crisis of the 1920s and 1930s, destabilizing liberal democracies and paving the road to dictatorship and a cataclysmic world war. Why risk a relapse now into economic isolationism?
Trump offers three logic-defying explanations. First, he parrots the populist left in blaming trade agreements for the decline of U.S. manufacturing jobs. Jacking up the price of imported goods, he assures us, will seed a new industrial boom at home.
Americans, however, aren't buying MAGAnomics. Consumer confidence has plummeted to a 12-year low, with families cutting back on spending in anticipation of a return to high living costs.
Investors are rattled too. By mid-March, the stock market had lost more than $3 trillion since Trump took office — the equivalent of 10 percent of America's $30 trillion GDP.
In a recent YouGov poll, 61 percent of voters said tariffs hurt average working people, while just 14 percent said they would help.
Trump touts tariffs as a magic elixir for growth, but their real purpose is to protect companies from foreign competition. Sometimes that's necessary for strategic reasons, to ensure access to vital goods during wars or other emergencies. Targeted and temporary tariffs can give struggling firms breathing room to adapt to changing market conditions.
Over time, however, a general policy of high tariffs invariably leads to economic scarcity and stagnation.
Second, Trump thinks trade deficits are proof that other countries are ripping us off.
'For decades, our country has been looted, pillaged, raped and plundered by nations near and far, both friend and foe alike,' he declared.
This eruption of paranoid nonsense shows Trump has no idea of how trade works. Comparative advantage makes trade a win-win proposition, which is why all countries, even hermetic North Korea, engage in it. Nor does the president understand how America's low savings rate and borrowing make our trade deficits larger.
Third, he hypes tariffs as a major new revenue stream for funding the federal government. White House aide Peter Navarro estimates tariffs will generate $600 billion a year, but Washington spends nearly $7 trillion a year. And if tariffs work as advertised, the revenue they generate will shrink as consumers avoid high-priced imports.
Trump's tariffs are a quack remedy for a real socioeconomic problem: The disappearance of manufacturing jobs with good pay and benefits since the 1970s has hit working families hard, even as the country as a whole has prospered.
That inequity has meant downward mobility and eroding social status as non-college workers struggle to find jobs that pay middle-class wages. Once thriving blue-collar communities feel abandoned by society and drawn to right-wing populism as they contend with shriveled economic prospects, family instability and drug addiction.
The president apparently sees tariffs as a form of reparations for working Americans. But the culprit isn't trade or globalization or 'neoliberalism.' It's the emergence of a post-industrial economy shaped mainly by technological change, rising education levels and growing demand for services.
Factory employment has declined in all advanced countries, even manufacturing powerhouses like Germany and Japan. But thanks to tech-driven productivity gains, U.S. manufacturing output has increased by more than 60 percent since 1999, even as our factory workforce has contracted by about 25 percent.
The U.S., like most other high-income countries, has evolved into a predominantly service-based economy. Services account for 80 percent of non-farm jobs. Even if more factories sprout up here, job gains are likely to be modest due to automation.
In fact, since Trump's first set of tariffs, manufacturing employment has stagnated, up by only 30,000 since 2018, compared to 400,000 in the second Obama term.
And with over half a million manufacturing jobs open over the last five years, blue-collar workers themselves appear ambivalent about factory careers.
A 2023 YouGov poll commissioned by the Progressive Policy Institute asked non-college workers where they think their children will find the best jobs and careers. Most (44 percent) choose the communications and digital economy, while just 13 percent picked manufacturing.
Yet Trump is threatening to tank the U.S. economy and poison relations with our trading partners to roll back five decades of post-industrial evolution. It's a mad quest, and working Americans will pay dearly for it.
Will Marshall is the founder and president of the Progressive Policy Institute.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Upturn
24 minutes ago
- Business Upturn
Online Tax Firm MyExpatTaxes Alerts Expats: Final Chance to Claim 2021 Stimulus Payments
Vienna, June 10, 2025 (GLOBE NEWSWIRE) — MyExpatTaxes, a leading US expat tax company known for its support of U.S. citizens living overseas, is highlighting an important upcoming deadline for American expatriates. By June 16th, expats must act to claim the 2021 stimulus payments. This deadline represents the final opportunity for expats who haven't already to benefit from COVID-19 economic stimulus payments, which can total thousands of . MyExpatTaxes is urging individuals not to miss out on this opportunity. As the U.S. is one of just two countries that taxes based on citizenship rather than residence, Americans living abroad have to report their worldwide income by filing a U.S. tax return every year. Many Americans expats are unaware of this requirement to file from overseas though, so get behind in their filing. The IRS has an amnesty program for these expats though called the Offshire Streamlined Filing Compliance Procedures. This process offers a chance for overseas Americans who have unintentionally failed to meet their filing obligations to catch up on their U.S. tax filing without facing penalties. It requires submitting the last three years of tax returns and, where applicable, up to six years of Foreign Bank and Financial Accounts Reports (FBARs). The procedure can seem complex, but with MyExpatTaxes offering either self-service or guided assistance, expats can find a sense of relief with easy access to tools like a US expat tax calculator and a stimulus check calculator found on their website. Nathalie Goldstein, CEO of MyExpatTaxes, underscores the significance of acting before the June 16th deadline for non-compliance overseas Americans, saying, 'The June 16th 2025 deadline is the last opportunity for American expatriates who may not have been aware that they have to file U.S. taxes from abroad to claim teh COVID-19 stimulus payments. It's also a valuable opportunity to get tax compliant without facing penalties. Our goal is to provide them with the guidance they need to make the most of these benefits.' Her words reflect the broader mission of MyExpatTaxes – supporting American expats in navigating what can often be a daunting process filing from overseas (often as well as filing taxes in the country where they reside). The 2021 expanded Child Tax Credit is also available for American families living abroad. This credit offers a substantial benefit of up to $3,600 per child, refundable for qualifying families. Timely filing is critical to claim this credit, ensuring families don't inadvertently miss out. To aid in this, expats can access comprehensive guidance and information on the Streamlined Procedures through MyExpatTaxes' dedicated page: Adding to the firm's efforts, Goldstein remarks, 'The potential gains for catching up and filing for 2021 for expats who qualify for the stimulus payments are typically far outweigh the costs of becoming compliant. Our platform is designed to simplify the tax filing process for U.S. citizens abroad, offering practical solutions and expert support. With the deadline imminent to claim these valuable payments, we're dedicated to helping expatriates claim what they are rightfully owed.' This statement emphasizes MyExpatTaxes' commitment to easing the stress associated with U.S. tax filing for expats. To further assist expats, the company has developed easy-to-use resources such as tax guides, quick start checklists, and webinars available on their website. These resources provide education and support, aimed at simplifying and demystifying the intricacies of international tax reporting for Americans living abroad. User testimonials and official reviews highlight the effectiveness and reliability of MyExpatTaxes' services, reinforcing their reputation as a helpful aid for expats. As the June 16th deadline approaches, expats need to be vigilant. Missing this date means losing out on the chance to claim the stimulus payments for good. Through proactive action and using MyExpatTaxes' offerings, expatriates can not only ensure compliance but also capitalize on available benefits. MyExpatTaxes remains committed to guiding expatriates through these important periods, helping them understand and fulfill their tax responsibilities while maximizing their eligible claims. For those seeking to learn more or benefit from these services, they can learn more through the platform's site: The resources provided are not just about fulfilling obligations – they also empower expats to take control of their financial responsibilities with confidence. ### For more information about MyExpatTaxes, contact the company here: MyExpatTaxesMackenzie Passegger [email protected]


Business Upturn
24 minutes ago
- Business Upturn
HistoSonics and Cambridge University Unveil Europe's First Edison™ Histotripsy System Powered by Li Ka Shing Foundation Gift
MINNEAPOLIS, United States: HistoSonics, the manufacturer of the Edison® Histotripsy System and novel histotripsy therapy platforms, announced today that Addenbrookes Hospital of Cambridge University Hospital Foundation and Trust will be the first site in the United Kingdom and European continent to offer histotripsy to both NHS and private patients. This was made possible through a generous donation by the Li Ka Shing Foundation (LKSF) as well as the expedited limited market access granted by the MHRA in April 2025. This press release features multimedia. View the full release here: The milestone marks HistoSonics' official entry into the UK and European market. HistoSonics won a coveted place in the Innovative Device Access Pathway pilot in 2024 and through this program, in partnership with the DHSC, MHRA, NIHR, NHSE, and NICE expedited access to patients. HistoSonics will continue to work with UK healthcare stakeholders on our aligned goal of urgently expanding access for all NHS patients. The Li Ka Shing Foundation, established in 1980 by Hong Kong philanthropist Sir Ka-shing Li, has contributed nearly US$4 billion to advancing education, medical research and services, and poverty alleviation across the USA, UK, Canada, and Asia. Recognizing the transformative potential of technological innovation in healthcare, the Foundation's latest gift to the University of Cambridge will build upon its previous donations of five Edison systems with three to Hong Kong, one to Singapore, and one recently to Stanford University. This new gift not only heralds the introduction of the first Edison system in the UK and Europe but also celebrates the enduring partnership between the Li Ka Shing Foundation and Cambridge in their collaborative efforts to fight cancer. By supporting cutting-edge medical technologies that can deliver low cost and highly efficient solutions, the Foundation hopes to enhance patient access with improved healthcare around the world. 'This donation is an historic milestone that brings non-invasive treatment of liver tumors using histotripsy to the UK,' said Mike Blue, President and CEO, HistoSonics. 'We are grateful to the Li Ka Shing Foundation for their visionary support. With Addenbrookes as our first NHS hospital site under UCNA, we are laying the foundation for future expansion into innovation driven hospitals across the UK.' The Edison System, which received FDA De Novo clearance in October 2023, uses non-invasive therapeutic focused ultrasound energy to mechanically destroy and liquefy targeted tissue and tumors without the invasiveness or toxicity of traditional procedures, reducing the risks of bleeding, infection, and damage to surrounding non-targeted tissue. HistoSonics' initial FDA clearance is for the destruction of liver tumors, with ongoing studies focusing on kidney tumors (HOPE4KIDNEY Trial NCT05820087) and pancreas tumors (GANNON Trial NCT06282809). Professor Deborah Prentice, Vice-Chancellor of the University of Cambridge, said: 'We are very fortunate that through the generosity of Sir Ka-shing Li, Addenbrooke's Hospital in Cambridge will be able to use cutting-edge histotripsy technology to improve outcomes for NHS patients. It is technology such as this that allows Cambridge to remain at the forefront of understanding and treating tumors, a position we aim to strengthen further with Cambridge Cancer Research Hospital.' With installations soon to be in five countries including the US, UK, Hong Kong, Singapore and the United Arab Emirates, HistoSonics is actively expanding access to its histotripsy platform and is working closely with clinical leaders, national health systems, and philanthropic partners to accelerate global adoption of histotripsy as a new category of health care. HistoSonics is also pursuing broader UK and European market access via CE marking. United Kingdom Intended Use Statement: The Edison System is intended for the non-invasive mechanical destruction of liver tumours, including the partial or complete destruction of unresectable liver tumours via histotripsy. This includes malignancy linked to primary liver cancer and cases of metastatic disease in the liver. The device should only be used by people who have completed training performed by HistoSonics Inc., and its use guided by the clinical judgement of an appropriately trained physician. Users must read this user guide to understand the warnings, precautions, and clinical trial summary, including reported adverse events. The Edison System has not been evaluated for the treatment of any specific disease, including, but not limited to, cancer or evaluated any specific cancer outcomes (such as local tumour progression, 5-year survival or overall survival). United States Intended Use Statement: The Edison System is intended for the non-invasive mechanical destruction of liver tumors, including the partial or complete destruction of unresectable liver tumors via histotripsy. The FDA has not evaluated the Edison System for the treatment of any disease including, but not limited to, cancer or evaluated any specific cancer outcomes (such as local tumor progression, 5-year survival or overall survival). The System should only be used by physicians who have completed training performed by HistoSonics, and its use guided by the clinical judgment of an appropriately trained physician. Refer to the device Instructions for Use for a complete list of warnings, precautions, and a summary of clinical trial results, including reported adverse events. About HistoSonics HistoSonics is a privately held medical device company developing a non-invasive platform and proprietary sonic beam therapy utilizing the science of histotripsy, a novel mechanism of action that uses focused ultrasound to mechanically destroy and liquify unwanted tissue and tumors. The company is currently focused on commercializing their Edison System in the US and select global markets for liver treatment while expanding histotripsy applications into other organs like kidney, pancreas, prostate, and others. HistoSonics has offices in Ann Arbor, Michigan and Minneapolis, MN. For more information on the Edison Histotripsy System please visit: For patient-related information please visit: View source version on Disclaimer: The above press release comes to you under an arrangement with Business Wire. Business Upturn takes no editorial responsibility for the same.
Yahoo
25 minutes ago
- Yahoo
Ardian and ROYC Announce Partnership
STOCKHOLM, June 10, 2025--(BUSINESS WIRE)--ROYC, the leading global Platform-as-a-Service provider for alternative investments, and Ardian, one of Europe's largest private investment firms managing and advising $180 billion in AuM, are today happy to announce a partnership. ROYC will act as a key partner for Ardian in the rapidly growing private wealth segment in Europe. "We are proud to partner with Ardian, sharing the belief that technology and a data-driven approach are essential for enabling more LPs to invest in Ardian's funds cost-effectively", said Mathias Leijon, Founder & President of ROYC. Erwan Paugam, Head of Private Wealth Solutions at Ardian, added, "ROYC has made a strong impression on us with its technological platform and professionalism. They will be an important partner to expand our activities in private wealth and in particular for the fundraising of our Ardian Secondary Infrastructure Fund IX". About ROYC ROYC is the leading European B2B financial technology company that provides a complete private markets operating system, empowering private equity firms, banks, wealth managers, and multi-family offices to seamlessly access, distribute, and manage private investments at scale. As private markets expand, financial institutions require scalable, technology-driven solutions to manage complexity, optimizing fund operations, and delivering exceptional client experiences. ROYC combines state-of-the-art private markets technology with tailored fund structuring and investment solutions. Its intuitive, scalable platform replaces manual processes with automation and real-time data access, transforming how private market investments are managed across the entire fund lifecycle. About Ardian Ardian is a world-leading private investment firm, managing or advising $180bn of assets on behalf of more than 1,850 clients globally. Our broad expertise, spanning Private Equity, Real Assets and Credit, enables us to offer a wide range of investment opportunities and respond flexibly to our clients' differing needs. Through Ardian Customized Solutions we create bespoke portfolios that allow institutional clients to specify the precise mix of assets they require and to gain access to funds managed by leading third-party sponsors. Private Wealth Solutions offers dedicated services and access solutions for private banks, family offices and private institutional investors worldwide. Ardian's main shareholding group is its employees and we place great emphasis on developing its people and fostering a collaborative culture based on collective intelligence. Our 1,050+ employees, spread across 19 offices in Europe, the Americas, Asia and Middle East are strongly committed to the principles of Responsible Investment and are determined to make finance a force for good in society. Our goal is to deliver excellent investment performance combined with high ethical standards and social responsibility.